noscript

News and Announcements

AUM Biosciences Establishes Joint Lab with A*STAR’s Singapore Immunology Network (SIgN) to Accelerate the Development of Targeted Cancer Therapies

  • Published August 20, 2020 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

SINGAPORE (18 August 2020) – AUM Biosciences (AUM), a Singapore-headquartered clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology, today announced that together with A*STAR’s Singapore Immunology Network (SIgN), a new joint lab will be established in Singapore, centred on drug development and immuno-monitoring of novel oncology drugs.

Housed in SIgN’s premises at Biopolis, Singapore’s biomedical research hub, the joint lab will focus on the discovery of novel and proprietary immune biomarkers and underlying drug mechanisms of action that will be used to better inform clinical trial design and study endpoint analysis. Combining SIgN’s scientific expertise in translational immunology, preclinical, and computational research with AUM’s extensive capabilities in clinical trial design and management will lead to better-targeted development programs for AUM’s cancer therapies.

Professor Lam Kong Peng, Executive Director of SIgN, added, “We are excited to bring SIgN’s expertise in translational immunology to the joint lab to help accelerate the development of novel cancer therapies, and to support Singapore’s vibrant biotech scene through our collaboration.”

Cancer remains a major medical concern with one in every six deaths being related to the disease. Recent disruptive discoveries in cancer therapy have highlighted the critical role of targeting the host immune system in regulating cancer progression. The AUM – SIgN partnership is timely to synergize drug development and immune profiling efforts to advance the development of multiple small molecules through preclinical and clinical trials with the ultimate goal of bringing these novel oncology drugs to market.

Dr. Harish Dave, CMO of AUM Biosciences, stated “AUM Biosciences is delighted to partner with SIgN in this exciting public-private collaboration. This represents the coming together of the best in translational research and industry to meet a common goal of delivering effective cancer therapeutics to patients.”

Access AUM Biosciences’ Deal Room here.

About AUM Biosciences

AUM Biosciences is an award-winning, oncology-focused biotechnology company that aims to accelerate the development of innovative, affordable cancer medicines for patients in Asia and around the world. AUM Biosciences focuses on early-stage development of innovative medicines for the treatment of Asian-prevalent cancers.

The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR). AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation. For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.

Register Interest

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now